Ask about this productRelated genes to: CAMKV antibody
- Gene:
- CAMKV NIH gene
- Name:
- CaM kinase like vesicle associated
- Previous symbol:
- -
- Synonyms:
- MGC8407, VACAMKL
- Chromosome:
- 3p21.31
- Locus Type:
- gene with protein product
- Date approved:
- 2005-03-04
- Date modifiied:
- 2018-06-04
Related products to: CAMKV antibody
Related articles to: CAMKV antibody
- INTRODUCTION: Gastric cancer remains a major global health burden with high incidence and mortality. Despite therapeutic advances, long-term survival remains unsatisfactory. Reliable biomarkers to predict therapeutic efficacy and clinical outcomes are urgently needed. This study aimed to elucidate the heterogeneity of gastric cancer using an integrative bioinformatics approach that combines single-cell RNA-sequencing (scRNA-seq) and bulk RNA-seq data. METHODS: scRNA-seq datasets were obtained from the GEO database, and bulk RNA-seq data were obtained from the TCGA. Cell communication, pseudotime analysis, and cell death scoring (cuproptosis, ferroptosis, autophagy, and pyroptosis) were performed on the basis of the scRNA-seq datasets. Stemness, survival, drug sensitivity and posttranslational modification (PTM) analyses were conducted using TCGA data. RESULTS: Cancer cells were clustered into three molecular subtypes with distinct molecular characteristics, pathway activation profiles and cell death patterns. Cell-cell communication analysis revealed subtype-specific regulatory interactions, whereas pseudotime and cell death scoring demonstrated dynamic cellular states. Bulk RNA-seq revealed five cell death patterns, among which "cell death 2" and high cuproptosis scores emerged as independent risk factors for poor prognosis. Genes such as LMF1-AS1, CAMKV, ERVW-1, ACLY, GAS2L2, RGS8, and RASSF8-AS1 were differentially expressed in the high-risk group. Samples with low stemness and elevated pyroptosis showed enhanced inferred drug resistance, particularly to LBH589. Additionally, ZDHHC22 was identified as a potential protective prognostic factor, and in vitro assays suggested its association with cell death modulation in gastric cancer. CONCLUSION: This study highlights the molecular heterogeneity of gastric cancer, demonstrating how distinct cell death patterns and PTM features shape prognosis and drug sensitivity. The identified biomarkers and resistance profiles may provide valuable guidance for personalized therapeutic strategies. - Source: PubMed
Publication date: 2026/05/30
Wu JiamingChen CongDou GuangjianHuang LiyongZhu YiChen ZhihengMao QileJia JingyiWang PeterLi Jin - Long-term outcome data for stiff person spectrum disorder (SPSD) remain limited and sustained response to treatment varies. - Source: PubMed
Mangioris GeorgiosMcKeon AndrewBower James HVorasoot NisaDubey DivyanshuFlanagan Eoin PPittock Sean JZekeridou Anastasia - We examined the clinical course and risk factors for late onset neurotoxicities, including nerve palsies (IEC-NP) and parkinsonism (IEC-PKS), in patients with relapsed/refractory multiple myeloma (RRMM) treated with ciltacabtagene autoleucel (cilta-cel) in standard-of-care practice (SOC). Among 235 RRMM patients who received cilta-cel, 15 (6.4%) developed IEC-NP and 9 (3.8%) developed IEC-PKS with one patient developing both. Pre-infusion, patients with age >75 years, bone marrow plasma cells ≥20%, or involved free light chain ≥20 mg/dL had increased odds of IEC-PKS. Post-infusion, patients who developed ICANS, received higher cumulative steroid doses or received >1 dose of tocilizumab also had increased odds of IEC-PKS. High peak absolute lymphocyte count (ALCpeak) was a statistically significant predictor on univariate and multivariate analysis for IEC-NP and IEC-PKS. ALC ≥ 3 × 10/L was identified as a meaningful threshold (AUC = 0.838) to predict for late onset neurotoxicity. An ALC ≥ 3 × 10/L conferred a positive predictive value for delayed neurotoxicity of 31% vs a negative predictive value of 98% in patients with ALC < 3 × 10/L. All IEC-NP patients received steroid +/- IVIG; 87% had complete resolution of their cranial neuropathies (median 57 days). Four patients with IEC-PKS received cyclophosphamide (1.5-2 g/m) within 1-13 days of symptom onset and all had observable symptom improvement within 1-2 days. - Source: PubMed
Publication date: 2025/12/31
Lim Kenneth J CTan MelindaParrondo RicardoChhabra SaurabhDooley KatharineDe Menezes Silva Corraes AndreCarabenciov DarinGertz MorieHwa LisaHaily StephensKapoor PrashantKourelis TaxiarchisWarsame RahmaCook JoselleBinder MoritzBergsagel P LeifYadav UditWiedmeier-Nutor ErinGeyer SusanAilawadhi SikanderFonseca RafaelKumar ShajiZekeridou AnastasiaLin Yi - Between 2006 and 2008, cases of occupational inflammatory polyradiculoneuropathy (OIPN) were identified among U.S. swine abattoir workers exposed to aerosolized porcine neural tissue. While the clinical features of this occupational polyradiculoneuropathy/polyradiculopathy have been described, its immunologic basis remained unclear. - Source: PubMed
Publication date: 2025/12/02
Hinson Shannon RGupta PranjalParamasivan Naveen KDyck P James BLennon Vanda ALachance Daniel HKnight Andrew MRezk MohamedKarsten CarleyLaFrance-Corey Reghann GStaff Nathan PHrstka Sybil CWu JackKlein Christopher JZekeridou AnastasiaMcKeon AndrewPittock Sean JLleixà CintaQuerol LuisDasari SurendraMills John RDubey Divyanshu - - Source: PubMed
Publication date: 2025/10/01
Harahsheh EhabHammami M BakriGupta PranjalCostello Brian ALeibovich BradleyCheville John CZekeridou AnastasiaMcKeon AndrewPittock Sean JDubey Divyanshu